Plus thoughts on an overly simplistic look at the cost-effectiveness of psoriasis drugs
And we're not having a constructive dialogue about gene therapy
And 2024's first drug-pricing announcement: Iovance's Amtagvi will run $515,000
Plus a study that defines 31 different flavors of 'out-of-pocket spending'
Plus oodles of other items, including fascinating Health Affairs papers, updates on IRA lawsuits, and a must-read on pharma advertising
Plus a lot of Antonio Ciaccia (and I'm here for it)
Plus links to the latest effort to put GPOs under the microscope
And I have tallied up your grades on the Pfizer Super Bowl commercial ...
And a Super Bowl poll question for you all ...
A rare break in the action in DrugPricingLand means this is a good morning for reflection and deep work
And the net-price nuggets from yesterday's Senate hearing that went (almost) unnoticed
And a couple of IRA-lawsuit nuggets worth tracking on
